IDXG INTERPACE BIOSCIENCES, INC.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1054102 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-9.7%
TTM net income YoY355.8%
TTM EPS YoY217.6%
Revenue 3-yr CAGR-12.3%
Net income 3-yr CAGR—
Margins
Gross margin65.6%
Operating margin1.6%
Net margin58.1%
FCF margin7.6%
EBITDA margin3.0%
Returns
ROE179.8%
ROA88.6%
ROIC (approx.)6.2%
Asset turnover1.53x
Leverage & solvency
Liabilities / assets34.1%
Debt / equity0.00x
Current ratio2.06x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.16x
Accruals ratio74.5%
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $38.73M | $46.93M |
| Cost of revenue | $14.60M | $17.00M |
| Gross profit | $24.13M | $29.93M |
| R&D expense | $642,000 | $676,000 |
| SG&A expense | $9.48M | $9.49M |
| Operating income | $4.08M | $8.11M |
| Pretax income | $3.77M | $6.95M |
| Income tax | -$21.21M | $4,000 |
| Net income | $24.57M | $6.70M |
| EBITDA | $4.51M | $8.41M |
| EPS (basic) | 5.55 | 1.42 |
| EPS (diluted) | 0.89 | 0.40 |
| Weighted avg. shares (diluted) | 27.70M | 15.73M |
| Balance sheet | ||
| Cash & equivalents | $2.50M | $1.46M |
| Receivables | $5.65M | $8.54M |
| Inventory | $1.11M | $1.21M |
| Current assets | $9.90M | $11.77M |
| PP&E, net | $1.42M | $1.36M |
| Total assets | $33.84M | $14.79M |
| Current liabilities | $5.10M | $10.62M |
| Total liabilities | $11.47M | $17.01M |
| Shareholders' equity | $22.36M | -$2.22M |
| Shares outstanding | 885,708 | 4.41M |
| Cash flow statement | ||
| Operating cash flow | $5.83M | $4.65M |
| Capital expenditure | $356,000 | $876,000 |
| Free cash flow | $5.47M | $3.77M |
| Investing cash flow | -$356,000 | -$876,000 |
| Financing cash flow | -$4.43M | -$5.81M |
| Depreciation & amortization | $425,000 | $300,000 |
| Stock-based compensation | $35,000 | $291,000 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.